Key Points • Murine allogeneic anti-CD19 CAR T cells integrated before or early after PTCy for allo-HCT can clear leukemia without added toxicity.• Clinical translation of this approach would combine… Click to show full abstract
Key Points • Murine allogeneic anti-CD19 CAR T cells integrated before or early after PTCy for allo-HCT can clear leukemia without added toxicity.• Clinical translation of this approach would combine the activity of both CAR T cells and polyclonal alloreactive T cells to reduce relapse.
               
Click one of the above tabs to view related content.